login

Endocrine and receptor pharmacology of serotonergic anxiolytics, antipsychotics and antidepressants

Life SciencesPublished 1 January 1992
Andrew D. Levy, Louis D. Van de Kar
Citations72
SJR quartileQ1
SJR score1.31
SNIP1.07

TL;DR

The receptor binding profiles of 5-HT anxiolytics, antipsychotics and antidepressants with their endocrine effects are compared to aid in understanding both the therapeutic and side effects of these drugs.

Abstract

Several classes of drugs that modify serotonin (5-HT) neurotransmission are either currently used, or are being evaluated for their potential use in the treatment of anxiety, schizophrenia, and depression. 5-HT1A agonists are considered potential anxiolytics, while some atypical antipsychotics are potent 5-HT2 antagonists (and also have modest dopamine D2 affinity). Furthermore, there is a diverse group of serotonergic drugs that may be effective antidepressants. Secretion of ACTH, corticosterone/cortisol, prolactin, renin, oxytocin and vasopressin are stimulated by activation of different 5-HT receptor subtypes, while other neurotransmitter receptors also influence the secretion of these hormones. We compared the receptor binding profiles of 5-HT anxiolytics, antipsychotics and antidepressants with their endocrine effects. These comparisons could aid in understanding both the therapeutic and side effects of these drugs.

Keywords

MedicineNeuroscienceBiochemistry, Genetics and Molecular Biology